Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatme...
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 400
- Registration Number
- NCT05307705
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸DFCI, Boston, Massachusetts, United States
🇺🇸Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT05306340
- Locations
- 🇺🇸
Alabama Oncology - Bruno Cancer Center, Birmingham, Alabama, United States
🇺🇸Alaska Oncology and Hematology, Anchorage, Alaska, United States
🇺🇸The Dignity Health Cancer Institute, Phoenix, Arizona, United States
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Treadwell Therapeutics, Inc
- Target Recruit Count
- 44
- Registration Number
- NCT05251714
- Locations
- 🇺🇸
START - Mountain Region, West Valley City, Utah, United States
🇺🇸START San Antonio, San Antonio, Texas, United States
🇺🇸The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
(VELA) Study of BLU-222 in Advanced Solid Tumors
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 366
- Registration Number
- NCT05252416
- Locations
- 🇺🇸
Hospital of the Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
SMMART Adaptive Clinical Treatment (ACT) Trial
- Conditions
- Advanced Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Stage II Pancreatic Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Advanced Prostate CarcinomaRecurrent Adult Soft Tissue SarcomaRecurrent Breast CarcinomaStage IV Ovarian Cancer AJCC v8Advanced Malignant Solid NeoplasmAdvanced Ovarian Carcinoma
- Interventions
- Drug: AlectinibDrug: AlpelisibDrug: AnastrozoleBiological: AtezolizumabBiological: BevacizumabProcedure: BiopsyProcedure: Biospecimen CollectionDrug: CapecitabineDrug: CarboplatinDrug: CobimetinibDrug: EntrectinibDrug: EribulinDrug: FulvestrantBiological: Hyaluronidase-zzxf/Pertuzumab/TrastuzumabDrug: IrinotecanDrug: LetrozoleDrug: Nab-paclitaxelDrug: NiraparibDrug: OlaparibDrug: PaclitaxelDrug: PalbociclibBiological: PertuzumabOther: Quality-of-Life AssessmentBiological: TrastuzumabBiological: Trastuzumab EmtansineDrug: VemurafenibDrug: VinorelbineDrug: Vismodegib
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT05238831
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05230810
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
🇺🇸Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
- Conditions
- Interventions
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 35
- Registration Number
- NCT05226871
- Locations
- 🇨🇳
Mackay Memorial Hospital, Taipei, Taiwan
🇲🇽Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Nuevo LEÓN, Mexico
🇨🇳Hubei Cancer Hospital, Wuhan, Hubei, China
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Relay Therapeutics, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05216432
- Locations
- 🇺🇸
University of California-San Diego, San Diego, California, United States
🇺🇸Washington University School of Medicine St. Louis, Saint Louis, Missouri, United States
🇺🇸Rutgers University, New Brunswick, New Jersey, United States
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Nuvation Bio Inc.
- Registration Number
- NCT05191004
- Locations
- 🇺🇸
Pennsylvania Cancer Specialists and Research Institute, Gettysburg, Pennsylvania, United States
🇺🇸Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸Compassionate Cancer Care Research Inc., Fountain Valley, California, United States
Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 120
- Registration Number
- NCT05181033
- Locations
- 🇸🇬
Nationa University Hospital, Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.